This program contains embargoed material that will be presented at the ASBMR 2012
Annual Meeting in Minneapolis, Minnesota, USA, October 12-15, 2012.
If you are using this program on or before the day of presentation for a particular
abstract, please note that the abstracts submitted to the ASBMR 2012 Annual Meeting
are embargoed - that is, unavailable for public release in written, oral and electronic
communications - until one hour after they have been presented.
The ASBMR is sensitive to issues of commercial confidentiality and relevant aspects
of the U.S. Securities and Exchange Commission (SEC) Regulations. Therefore, all
users of the ASBMR 2012 Annual Meeting Abstracts Online and Itinerary Builder must
adhere to the Securities and Exchange Commission regulations and treat all information
as confidential until the embargo has been lifted - one hour after the abstract
has been presented. Users of this site may be viewed as "insiders" by the SEC due
to their knowledge of information included in abstracts, particularly clinical trial
abstracts. Acting on information included in these abstracts - prior to their public
release after the embargo has been lifted - may subject individuals to criminal
By clicking on the link below ("I AGREE"), you will acknowledge your understanding
of and agreement to uphold the ASBMR Embargo Policy, comply with the SEC Regulations,
and to keep the content of all ASBMR abstracts confidential until the embargo has
I understand the ASBMR Embargo Policy, which is that ASBMR abstracts are unavailable
for public release in written, oral and electronic communications - until one hour
after an abstract or abstracts has/have been presented.
Furthermore, I agree that under no circumstances will I share with others the information
from abstracts or the abstracts themselves, nor will I make use of any "insider"
information gained by previewing ASBMR abstracts. The abstracts are available for
public release only after one hour following the time of their presentation.